A blood cancer drug developed by Kazakh scientists is expected to be tested as early as 2026. Volunteers will be recruited for this trial. The method is based on CAR-T therapy, which targets and destroys cancer cells without harming healthy ones. The treatment causes minimal side effects, and the patient’s immune system is not compromized.

Read more